(continue from previous posting)
Good news and progress, this is what we want. "European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” and includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and vitamins.
This is significant; European Patent Bulletin is something of a bible to biotech and pharma industry in Europe. Meaning all in the sector will know this at November 11 (at the latest). With both food and beverage (among others) applications, the LXRP technology will get attention in those markets - with a patent protection! Other markets mentioned are also a possibility, though often longer process to monetize IMO.
Maybe the most important; "Priority is granted to certain dates in 2014 and 2015, strengthening Lexaria’s IP claims compared to more recent competitors. This represents the first patent issuance in Europe under Lexaria’s first patent family." Again... with evolving DehydraTECH formula, Lexaria has a NEW POSITION; Stronger and updated formula, more diversified to different customers needs - with more applications - and now Patented in a 340 million people market. This can be a game changer.
"Lexaria currently has 18 granted patents (including nine granted in the US), along with approximately 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Pending patents are for the delivery of many antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more."
One (1) - is all it takes; if only one major company or conglomerate want to own/buy(license one of the patents, we will be looking at millions; cash/royalties and or other way of payment that will take Lexaria Bioscience to a international player in the biotech sector.
